Summary
GlobalData's Medical Devices sector report, “Total Artificial Heart - Medical Devices Pipeline Assessment, 2016" provides an overview of Total Artificial Heart currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Total Artificial Heart pipeline products.
This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type
Scope
- Extensive coverage of the Total Artificial Heart under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Total Artificial Heart under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Companies Mentioned
Abiomed, Inc.
BiVacor Pty Ltd
Carmat SAS
Cleveland Heart, Inc.
Foster-Miller, Inc.
MicroMed Cardiovascular, Inc.
SynCardia Systems, Inc.
The University of Tokyo
'
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Total Artificial Heart Overview 6
3 Products under Development 7
3.1 Total Artificial Heart - Pipeline Products by Stage of Development 7
3.2 Total Artificial Heart - Pipeline Products by Territory 8
3.3 Total Artificial Heart - Pipeline Products by Regulatory Path 9
3.4 Total Artificial Heart - Pipeline Products by Estimated Approval Date 10
3.5 Total Artificial Heart - Ongoing Clinical Trials 11
4 Total Artificial Heart - Pipeline Products under Development by Companies 12
4.1 Total Artificial Heart Companies - Pipeline Products by Stage of Development 12
4.2 Total Artificial Heart - Pipeline Products by Stage of Development 13
5 Total Artificial Heart Companies and Product Overview 14
5.1 Abiomed, Inc. Company Overview 14
5.1.1 Abiomed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 14
5.2 BiVacor Pty Ltd Company Overview 16
5.2.1 BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 16
5.3 Carmat SAS Company Overview 17
5.3.1 Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview 17
5.4 Cleveland Heart, Inc. Company Overview 21
5.4.1 Cleveland Heart, Inc. Pipeline Products & Ongoing Clinical Trials Overview 21
5.5 Foster-Miller, Inc. (Inactive) Company Overview 23
5.5.1 Foster-Miller, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 23
5.6 MicroMed Cardiovascular, Inc. Company Overview 24
5.6.1 MicroMed Cardiovascular, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24
5.7 SynCardia Systems, Inc. Company Overview 25
5.7.1 SynCardia Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 25
5.8 The University of Tokyo Company Overview 34
5.8.1 The University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview 34
6 Total Artificial Heart- Recent Developments 35
6.1 Apr 13, 2016: World’s Leading Artificial Heart Center, La Pitié Hospital, Paris, Celebrates 30 Years and 249 Implants of the SynCardia Total Artificial Heart 35
6.2 Feb 29, 2016: Early Findings of the 50cc SynCardia Heart Indicate That It Fits Underserved Patients - Women & Adolescents 36
6.3 Feb 26, 2016: Carmat Raises USD55 Million in Private Placement of Shares 37
6.4 Jan 26, 2016: Altaris Capital Partners Acquires Minority Interest in Minnetronix for USD20 Million 37
6.5 Jan 21, 2016: Information regarding the Feasibility study of the CARMAT bioprosthetic artificial heart 37
6.6 Nov 12, 2015: Arrhythmia Research Technology Reports 2015 Third Quarter Results 38
6.7 Sep 16, 2015: SynCardia Systems Withdraws IPO for up to USD30 Million 39
6.8 Aug 31, 2015: Interim Results of the Feasibility Study Presented at the ESC Congress in London 40
6.9 Aug 18, 2015: The Start of SynCardia Total Artificial Heart Destination Clinical Study Wins Edison Awards’ Top Honor 40
6.10 Jun 15, 2015: SynCardia Systems - TAH-t Companion 2 Driver System - Letter to Health Care Providers 41
6.11 Jun 03, 2015: Carmat To Implant Artificial Heart In Fourth Patient In Next Three Months 42
7 Appendix 43
7.1 Methodology 43
7.2 About GlobalData 45
7.3 Contact Us 46
7.4 Disclaimer 46
1.1 List of Tables
Table 1: Total Artificial Heart - Pipeline Products by Stage of Development 7
Table 2: Total Artificial Heart - Pipeline Products by Territory 8
Table 3: Total Artificial Heart - Pipeline Products by Regulatory Path 9
Table 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date 10
Table 5: Total Artificial Heart - Ongoing Clinical Trials 11
Table 6: Total Artificial Heart Companies - Pipeline Products by Stage of Development 12
Table 7: Total Artificial Heart - Pipeline Products by Stage of Development 13
Table 8: Abiomed, Inc. Pipeline Products & Ongoing Clinical Trials Overview 14
Table 9: AbioCor II - Product Status 15
Table 10: AbioCor II - Product Description 15
Table 11: BiVacor Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 16
Table 12: BiVACOR Device - Product Status 16
Table 13: BiVACOR Device - Product Description 16
Table 14: Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview 17
Table 15: Artificial Heart - Product Status 18
Table 16: Artificial Heart - Product Description 18
Table 17: Carmat SAS - Ongoing Clinical Trials Overview 19
Table 18: Artificial Heart - First-in-man CARMAT’s Bioprosthetic Heart Trial For End-stage Heart Failure 20
Table 19: Cleveland Heart, Inc. Pipeline Products & Ongoing Clinical Trials Overview 21
Table 20: SmartHeart TAH - Product Status 22
Table 21: SmartHeart TAH - Product Description 22
Table 22: Foster-Miller, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 23
Table 23: MagScrew Total Artificial Heart - Product Status 23
Table 24: MagScrew Total Artificial Heart - Product Description 23
Table 25: MicroMed Cardiovascular, Inc. Pipeline Products & Ongoing Clinical Trials Overview 24
Table 26: Pulse Less Total Artificial Heart - Product Status 24
Table 27: Pulse Less Total Artificial Heart - Product Description 24
Table 28: SynCardia Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 25
Table 29: 50cc Total Artificial Heart - Adults Bridge To Transplant - Product Status 26
Table 30: 50cc Total Artificial Heart - Adults Bridge To Transplant - Product Description 26
Table 31: 50cc Total Artificial Heart - Destination Therapy - Product Status 27
Table 32: 50cc Total Artificial Heart - Destination Therapy - Product Description 27
Table 33: 50cc Total Artificial Heart - Pediatric Bridge To Transplant - Product Status 28
Table 34: 50cc Total Artificial Heart - Pediatric Bridge To Transplant - Product Description 28
Table 35: SynCardia Temporary 70cc Total Artificial Heart - Destination Therapy - Product Status 29
Table 36: SynCardia Temporary 70cc Total Artificial Heart - Destination Therapy - Product Description 29
Table 37: SynCardia Systems, Inc. - Ongoing Clinical Trials Overview 30
Table 38: SynCardia Temporary 70cc Total Artificial Heart - Destination Therapy - SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT) 31
Table 39: 50cc Total Artificial Heart - Pediatric Bridge To Transplant - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant 32
Table 40: 50cc Total Artificial Heart - Adults Bridge To Transplant - SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant 33
Table 41: The University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview 34
Table 42: Total Artificial Heart - Product Status 34
Table 43: Total Artificial Heart - Product Description 34
Table 44: Glossary 44
1.2 List of Figures
Figure 1: Total Artificial Heart - Pipeline Products by Stage of Development 7
Figure 2: Total Artificial Heart - Pipeline Products by Territory 8
Figure 3: Total Artificial Heart - Pipeline Products by Regulatory Path 9
Figure 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date 10
Figure 5: Total Artificial Heart - Ongoing Clinical Trials 11
